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Antibody-mediated encephalitides constitute a group of in-flammatory brain diseases that are characterized by prominent neuropsy-chiatric symptoms and are associated with antibodies against neuronal 
cell-surface proteins, ion channels, or receptors (Table 1).1 Common clinical fea-
tures include a change in behavior, psychosis, seizures, memory and cognitive 
deficits, abnormal movements, dysautonomia, and a decreased level of conscious-
ness. There are, however, no systemic manifestations other than autonomic dys-
function, and this group of diseases is separable from traditional autoimmune 
disorders such as systemic lupus erythematosus, which may affect the nervous 
system. Also separate from this group of antibody-mediated encephalitides are 
several disorders, some of which are paraneoplastic, such as cerebellar degenera-
tion,2 neuromyelitis optica,3 and stiff-person spectrum diseases,4 that are associ-
ated with antibodies against neuronal or glial cell-surface antigens but that are 
rarely associated with the aforementioned symptoms.
The antibody-mediated encephalitides occur in persons of all ages, with some 
types affecting predominantly children and young adults. Certain syndromes are 
recognizable on clinical grounds, and their autoimmune cause can be established 
with laboratory tests. Despite the severity of symptoms, prompt diagnosis and 
treatment lead to improvement or full recovery in most cases. This review focuses 
on the encephalitides associated with autoantibodies against neuronal cell-surface 
antigens, for which there is compelling evidence that the antibodies have direct 
pathogenic effects.
Fr equenc y,  Immunol o gic Fe at ur es,  a nd A sso ci ated 
Disor der s
The estimated annual incidence of all types of encephalitis is approximately 5 to 
8 cases per 100,000 persons, and in 40 to 50% of the cases, the cause cannot be 
established.5 A prospective, multicenter, population-based study suggests that auto-
immune disorders are the third most common cause of encephalitis, after infec-
tions, usually viral, and acute disseminated encephalomyelitis, which is typically a 
postinfectious disorder.5 A study from a center that is specifically concerned with 
the epidemiology of encephalitis showed that the frequency of the most common 
form of autoimmune encephalitis, the type with antibodies against the N-methyl-d-
aspartate receptor (NMDAR), surpassed the frequency of any individual viral cause 
of encephalitis in young persons,6 and in one retrospective study, anti-NMDAR 
encephalitis accounted for 1% of all admissions of young adults to an intensive 
care unit.7 A retrospective Dutch study showed that encephalitis characterized by 
antibodies against leucine-rich, glioma-inactivated 1 (LGI1) was the second most 
frequent autoimmune encephalitis, with an incidence of 0.83 cases per 1 million 
persons.8
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Beginning in the 1980s, studies of paraneo-
plastic neurologic syndromes associated with 
antibodies against intracellular neuronal anti-
gens informed subsequent clinical and labora-
tory research on the autoimmune encephaliti-
des.9 The distinction between these two groups 
of disorders is important because some of the 
triggers and syndromes are similar but their 
pathogenic mechanisms and outcomes are dif-
ferent. A comparison of the antibodies associated 
with these two categories is shown in Figure 1A 
through 1F. In the autoimmune encephalitides, 
the antibodies bind to extracellular epitopes of 
cell-surface proteins and cause reversible neuro-
nal dysfunction.1 These features may explain the 
better outcomes for patients with autoimmune 
encephalitides, as compared with the outcomes 
for patients with neurologic syndromes relat-
ed to antibodies against intracellular proteins, 
in which neuronal loss is frequent and cyto-
toxic T-cell mechanisms predominate10 (Fig. 1G 
through 1J).
Most autoimmune encephalitides occur in 
patients with no apparent immunologic triggers, 
leading some investigators to postulate a genetic 
predisposition to these disorders. Two studies 
showed an association of anti-LGI1 encephalitis 
with HLA class II genes, including HLA-DRB1*07 
(DR7) and HLA-DRB4 in a Dutch population11 
and DRB1*07:01–DQB1*02:02 in a Korean popu-
lation.12 In the same two studies, no specific 
HLA association was found with anti-NMDAR 
encephalitis,12 but another study suggested a 
genetic predisposition in Maori and Pacific Island 
populations.13
Two potential triggers of autoimmune encepha-
litides are tumors (Table 1) and viral encephali-
tis. Some of the implicated tumors contain nerve 
tissue or the tumor cells express the neuronal 
proteins targeted by the autoantibodies,14 sug-
gesting that the ectopic expression of these 
proteins may play a role in initiating the autoim-
mune response. Herpes simplex encephalitis, 
and possibly other viral encephalitides, can trig-
ger antibodies against the NMDAR and other 
neuronal cell-surface proteins; such antibodies 
might explain relapsing neurologic symptoms 
that arise weeks after the onset of herpes sim-
plex encephalitis.15,16 This delayed complication 
affects approximately 20% of patients with her-
pes simplex encephalitis and is manifested pre-
dominantly as choreoathetosis in children and as 
psychiatric and behavioral alterations in adults.15,17 
Immunotherapy with glucocorticoids, plasma ex-
change, intravenous immune globulin, or ritux-
imab is partially effective during relapse and 
does not appear to confer a predisposition to 
reactivation of the herpes simplex virus.18
Clinic a l S y ndromes
In most cases of autoimmune encephalitis, the 
clinical presentation and findings on magnetic 
Figure 1 (facing page). Antibody Reactivity  
and Pathological Features of Encephalitis Associated 
with Antibodies against Neuronal Cell-Surface Antigens 
as Compared with Encephalitis Associated with Antibodies 
against Intracellular Antigens.
In encephalitis associated with antibodies against cell-
surface antigens, the antibodies have access to the epi-
topes and can potentially alter the structure and function 
of the cognate antigen (Panel A), whereas in encephalitis 
associated with antibodies against intracellular antigens, 
the antibodies cannot reach the intracellular epitopes, 
and cytotoxic T-cell mechanisms are predominantly 
 involved (Panel B). N-methyl-d-aspartate receptor 
(NMDAR) antibodies (Panels C and E) are examples  
of the group of antibodies against cell-surface antigens, 
and Hu antibodies (Panels D and F) are examples of 
the group of antibodies against intracellular antigens. 
In immunofluorescence studies of rodent brain with tis-
sue permeabilized to allow entry of antibodies, NMDAR 
antibodies are characterized by a pattern of neuropil-like 
immunolabeling (Panel C, green staining), whereas Hu 
antibodies have a discrete pattern of cellular immuno-
labeling (Panel D, green staining). In contrast, with live 
cultured neurons, NMDAR antibodies have access to 
the target antigen (Panel E, intensive immunolabeling), 
whereas Hu antibodies cannot reach the intracellular 
antigen (Panel F, no immunolabeling). Autopsy studies 
have shown that patients with anti-NMDAR encephali-
tis have moderate brain inflammatory infiltrates along 
with plasma cells (Panel G, cells stained brown with  
a CD138 antibody), deposits of IgG (Panel H, diffuse 
brown staining with an antihuman IgG antibody), and 
microglial proliferation (Panel H inset, microglial cells 
stained red with a CD68 antibody), without evidence of 
T-cell–mediated neuronal loss (not shown). In contrast, 
patients with anti-Hu paraneoplastic encephalitis have 
extensive neuronal loss and inflammatory infiltrates 
(not shown); the T cells are in direct contact with neu-
rons (Panel I, arrows; hematoxylin and eosin), probably 
contributing to neuronal degeneration through perforin 
and granzyme mechanisms (Panel J, arrow; granzyme B 
staining). All human tissue sections (Panels G through J) 
were obtained from the hippocampus.
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resonance imaging (MRI) of the head and cere-
brospinal fluid (CSF) assessment resemble those 
in cases due to viral infection.19 Symptoms prog-
ress over a period of days or weeks, with the ex-
ception of some patients who have autoimmune 
encephalitis with antibodies against contactin-
associated protein–like 2 (CASPR2),8 dipeptidyl-
peptidase–like protein 6 (DPPX),20 or LGI1,21
which may have a more indolent course. Ap-
proximately 60% of patients with autoimmune 
encephalitis have prodromal low-grade fever, 
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toms are characteristic of particular types of 
autoimmune encephalitides — for example, fa-
ciobrachial dystonic seizures and paroxysmal 
dizzy spells occur with anti-LGI1 encephali-
tis,22,23 and severe diarrhea and weight loss occur 
in the prodromal phase of anti-DPPX encephalitis24 
(Table 1).
The disorders most frequently recognized on 
clinical grounds are anti-NMDAR encephalitis 
and limbic encephalitis. Anti-NMDAR encepha-
litis affects predominantly children and young 
adults (median age, 21 years), with a predomi-
nance of cases in females (4:1) that becomes less 
evident after the age of 45 years.25 Up to 58% of 
affected young female patients have an ovarian 
teratoma (extragonadal teratomas are a rare 
cause); in men and children, the association 
with tumors is less frequent.25 Young children 
typically present with insomnia, seizures, abnor-
mal movements, or a change in behavior such as 
irritability, temper tantrums, agitation, and re-
duction of verbal output. Teenagers and adults 
more often present with psychiatric symptoms, 
including agitation, hallucinations, delusions, 
and catatonia, which may lead to hospital ad-
mission for psychosis. The disease progresses in 
a period of days or weeks to include reduction of 
speech, memory deficit, orofacial and limb dys-
kinesias, seizures, decreased level of conscious-
ness, and autonomic instability manifested as 
excess salivation, hyperthermia, fluctuations of 
blood pressure, tachycardia, or central hypoven-
tilation.26 Bradycardia and cardiac pauses are 
infrequent but require a temporary pacemaker in 
some patients. One month after disease onset, 
regardless of the symptoms at presentation, 
most children and adults have a syndrome that 
combines several of the above-mentioned symp-
toms; in approximately 5% of patients, the dis-
ease may remain monosymptomatic (e.g., psychi-
atric symptoms).25
MRI of the head is abnormal in 30% of af-
fected patients, mainly showing increased fluid-
attenuated inversion recovery (FLAIR) signal 
involving the cortical, subcortical, or cerebellar 
regions (Fig. 2A).25 The diagnosis of anti-NMDAR 
encephalitis is confirmed by the detection of 
CSF antibodies against the GluN1 subunit of the 
NMDAR; serum testing is less reliable, with 
false negative results in up to 14% of cases.27 In 
children who have symptoms suggestive of anti-
NMDAR encephalitis but with discordant MRI 
changes involving the basal ganglia and brain 
stem, the possibility of encephalitis due to anti-
bodies against the dopamine 2 receptor should 
be considered (Fig. 2B).28
In contrast to anti-NMDAR encephalitis, lim-
bic encephalitis can result from immune re-
sponses against several different neuronal cell-
surface proteins (Table 1).19 Patients with limbic 
encephalitis are usually older than 45 years, with 
a sex predominance that varies with the type of 
antibody (Table 1). Symptoms include confusion, 
behavioral changes, seizures, and inability to 
form new memories, with relative preservation 
of the old ones. The MRI scan shows increased 
FLAIR signal in the medial aspect of the tempo-
ral lobes, which in rare cases is enhanced with 
gadolinium infusion. In some cases, the MRI 
scan is normal or shows unilateral changes 
(Fig. 2C). If only one temporal lobe is involved, 
the differential diagnosis includes cortical edema 
from ongoing seizures, glioma, and herpes sim-
plex encephalitis.
The likelihood and type of underlying tumor 
and the response to treatment differ according 
to the type of limbic encephalitis. LGI1 antibod-
ies account for the majority of cases of limbic 
encephalitis, and hyponatremia is a feature of 
65% of these cases; an underlying tumor is 
rare.21 Limbic encephalitis associated with anti-
bodies against γ-aminobutyric acid (GABA) 
type B receptor (GABABR) and that associated 
with antibodies against α-amino-3-hydroxy- 
5-methyl-4-isoxazolepropionic acid receptor 
(AMPAR) are the next most frequent types of 
limbic encephalitis; 50 to 60% of patients with 
limbic encephalitis due to one of these antibod-
ies have cancer (Table 1).29,30 Limbic encephali-
tis can also be a manifestation of the aforemen-
tioned conventional paraneoplastic syndromes 
with antibodies against intracellular antigens 
(e.g., Hu and Ma2)9 or the 65-kD isoform of 
glutamic acid decarboxylase (GAD65). These 
syndromes usually respond less well to immu-
notherapy than do the autoimmune encepha-
litides.19
Other autoimmune encephalitides (Table 1) 
have less distinctive symptoms and MRI find-
ings. Certain clinical features nevertheless sug-
gest a specific type of autoimmune encepha-
litis, such as refractory status epilepticus with 
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GABA type A receptor (GABAAR) antibodies; 
encephalopathy, insomnia, dysautonomia, 
ataxia, peripheral-nerve hyperexcitability, and 
neuropathic pain with CASPR2 antibodies23,31; 
and myoclonus, tremors, and exaggerated star-
tle responses (hyperekplexia) with DPPX anti-
bodies.20,24
In most autoimmune encephalitides, the MRI 
is normal or shows nonspecific inflammatory 
changes; two exceptions are limbic encephalitis 
Figure 2. MRI Findings in Antibody-Mediated Encephalitis.
Shown are representative MRI scans from patients with several types of autoimmune encephalitides. Anti-NMDAR 
encephalitis often is present despite normal MRI findings or mild signal abnormalities on fluid-attenuated inversion 
recovery (FLAIR) images (Panel A). Basal ganglia encephalitis associated with dopamine 2 receptor antibodies typi-
cally affects the striatum (Panel B). Limbic encephalitis may result from several different immune responses and is 
typically indicated by FLAIR signal increases in the medial temporal lobes (Panel C). In contrast, encephalitis with 
antibodies against γ-aminobutyric acid (GABA) type A receptor (GABAAR ) is usually associated with multiple corti-
cal and subcortical FLAIR signal changes (Panel D). Patients with various acute inflammatory demyelinating diseases 
may have clinical and MRI findings that are indistinguishable from the findings in patients with autoimmune encepha-
litis. For example, an MRI scan showing extensive, bilateral FLAIR signal abnormalities was obtained from a patient 
in whom sudden-onset confusion and encephalopathy developed that were caused by acute disseminated encepha-
lomyelitis associated with antibodies against myelin oligodendrocyte glycoprotein (Panel E). The clinical and radio-
logic features of autoimmune encephalitides can occasionally be misleading. For example, a young man was admit-
ted for severe encephalitis and refractory seizures that required pharmacologically induced coma. Studies showed a 
large thymoma, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) antibodies, and MRI find-
ings (Panel F) that suggested widespread cortical damage and a poor prognosis. However, removal of the tumor 
and immunotherapy resulted in complete clinical recovery.
A B C
E FD
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and anti-GABAAR encephalitis. In GABAAR en-
cephalitis, which occurs predominantly in chil-
dren and young adults, FLAIR images show 
multifocal cortical and subcortical signal abnor-
malities, mainly in the frontal and temporal 
lobes and less frequently in the cerebellum and 
basal ganglia.32 These lesions do not show diffu-
sion restriction or contrast enhancement and 
resemble the lesions in acute disseminated en-
cephalomyelitis (Fig. 2D).
Most patients with autoimmune encephalitis 
have moderate CSF lymphocytic pleocytosis 
(<100 cells per cubic millimeter), but the absence 
of pleocytosis does not rule out the diagnosis. The 
encephalitides with LGI1 or DPPX antibodies are 
the ones that most frequently occur with normal 
MRI findings and normal results of standard 
CSF studies (cell count and protein and glucose 
levels).20,21 In most patients with autoimmune 
encephalitis, even those with normal findings 
on standard CSF studies, neuronal autoantibodies 
are detected in CSF.19 However, some patients 
with anti-LGI1 encephalitis have antibodies that 
are detectable only in serum23 or only in CSF.21
The differential diagnosis of autoimmune 
encephalitis, which is extensive,19 includes acute 
disseminated encephalomyelitis, characterized by 
MRI abnormalities throughout white and gray 
matter and frequent detection of autoantibodies 
against myelin oligodendrocyte glycoprotein 
(Fig. 2E), and neuromyelitis optica spectrum dis-
orders, in which the MRI abnormalities are often 
adjacent to periventricular and ependymal regions 
and most patients have antibodies against the 
water channel aquaporin-4, which is expressed in 
the endfeet of astrocytes. For unexplained rea-
sons, these demyelinating syndromes can de-
velop concurrently with anti-NMDAR encephali-
tis, resulting in overlapping clinical syndromes.33 
The clinical and MRI features of autoimmune 
encephalitides can occasionally suggest a neuro-
degenerative process21 or irreversible brain dam-
age reflected by restricted diffusion in regions of 
the cerebral cortex (Fig. 2F). Clinical recognition 
of these atypical presentations of autoimmune 
encephalitides is important because they are 
potentially treatable with immunotherapy.
Mech a nisms of Dise a se
The target antigens in autoimmune encephaliti-
des are cell-surface proteins involved in neuronal 
signaling and synaptic plasticity.1 The associated 
syndromes show substantial resemblance to the 
syndromes observed when the function of the 
same proteins is altered by genetic modification 
or pharmacologic antagonists. For example, 
many clinical features of anti-NMDAR encepha-
litis resemble those observed with the adminis-
Figure 3 (facing page). Proposed Mechanisms of Disease 
and Functional Interactions of Autoantibodies  
with Neuronal Surface Proteins.
A multistep process results in antibody-mediated neu-
ronal cell dysfunction; some of the steps have been 
shown in reported studies, whereas others are based 
on proposed hypotheses. Two well-known triggers of 
autoimmune encephalitides are represented: herpes 
simplex virus (Panel A) and systemic tumors (Panel B). 
It is postulated that antigens released by virus-induced 
neuronal cell destruction or apoptotic tumor cells are 
loaded into antigen-presenting cells (dendritic cells) 
and transported to regional lymph nodes.9 In the lymph 
nodes, naive B cells exposed to the processed antigens, 
in conjunction with CD4+ T cells, become antigen- 
conditioned and differentiate into antibody-producing 
plasma cells. After entering the brain, memory B cells 
undergo restimulation, antigen-driven affinity matura-
tion, clonal expansion, and differentiation into antibody-
producing plasma cells (Panel C).35 The contribution  
of systemically produced antibodies to the pool of anti-
bodies present in the brain is unclear and may depend 
on systemic antibody titers and the integrity of the 
blood–brain barrier. On the basis of experimental 
models with cultured neurons, the presence of anti-
bodies in the brain may lead to neuronal dysfunction 
through various mechanisms, including functional 
blocking of the target antigen (GABA type B receptor 
[GABABR] antibodies, Panel D), receptor cross-linking 
and internalization (NMDAR antibodies, Panel E), and 
disruption of protein–protein interactions (leucine-rich, 
glioma-inactivated 1 [LGI1]), potentially affecting the 
function of the voltage-gated potassium channels and 
leading to a decrease in the levels of AMPAR (Panel F).1 
These mechanisms are influenced by the type of anti-
bodies; for example, IgG1 antibodies frequently cross-
link and internalize the target antigen, but IgG4 anti-
bodies are less effective in cross-linking the target and 
more often alter protein–protein interactions. A graph 
based on an in vivo model (Panel G) shows how anti-
bodies from patients with anti-NMDAR encephalitis 
cause symptoms. In this mouse model, passive cere-
broventricular infusion of antibodies during 14 days 
was associated with a progressive increase in brain-
bound human antibodies, which was maximal on day 18. 
The antibodies caused a progressive decrease in syn-
aptic NMDAR and loss of memory. All findings were 
reversed a few days after cessation of the antibody in-
fusion, including a gradual decrease in levels of anti-
bodies in the mouse hippocampus and restoration of 
the density of synaptic NMDAR and memory function.36
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tration of noncompetitive NMDAR antagonists 
(ketamine or phencyclidine).34 The ways in 
which the immune response is initiated and 
the antibodies reach or are produced in the 
brain are starting to be elucidated. It has been 
postulated that the autoimmune response is 
initiated by antigens released by the viral de-
struction of neurons (e.g., in herpes simplex 
encephalitis) (Fig. 3A), by tumors (Fig. 3B), or 
by unknown mechanisms. In the case of anti-
NMDAR encephalitis, there is preliminary evi-
dence that memory B cells reach the brain, 
where they undergo restimulation, antigen-
driven affinity maturation, clonal expansion, 
and differentiation into antibody-producing 
plasma cells (Fig. 3C). This is supported by 
brain biopsy and autopsy studies showing plas-
ma cells (Fig. 1G), deposits of IgG (Fig. 1H), and 
reduced levels of NMDAR37,38 and by CSF stud-
ies showing an ongoing, antigen-driven, intra-
thecal immune response characterized by clon-
ally expanded plasma cells producing antibodies 
against NMDAR.35 Similar mechanisms may ap-
ply to those autoimmune encephalitides that 
are also characterized by intrathecal synthesis 
of antibodies, little clinical evidence of blood–
brain barrier disruption, and low or undetect-
able serum antibody levels in patients with se-
vere deficits.
For all autoimmune encephalitides, patho-
genic effects of the antibodies have been shown 
in primary cultures of neurons. These effects 
include blocking of receptor function (e.g., in 
the case of GABABR), cross-linking and internal-
ization of receptors (NMDAR),38,39 and interfer-
ence with protein–protein interactions (LGI1)40 
(Table 1 and Fig. 3D, 3E, and 3F). Even though 
some antibodies are of subclass IgG1 or IgG3, 
there is limited evidence that complement fixa-
tion plays a major role in autoimmune encepha-
litides.10,37 In a mouse model involving passive 
cerebroventricular transfer of antibodies from 
the CSF of affected patients36,41 or of a human 
recombinant antibody derived from CSF plasma 
cells,35 the antibodies disrupted the interaction 
between NMDAR and the ephrin-B2 receptor, 
leading to receptor internalization, impairment 
of long-term synaptic plasticity, memory defi-
cits, anhedonia, and depressive behaviors. These 
alterations gradually resolved after the antibody 
infusion was stopped (Fig. 3G).36 The pathoge-
nicity of NMDAR antibodies from affected pa-
tients has been suggested in other experimental 
models.42,43 No animal models are available for 
other autoimmune encephalitides.
Tr e atmen t s a nd Ou t come
Treatment recommendations are based largely 
on retrospective series and expert opinion, since 
few clinical trials have been conducted. The cur-
rent approach includes immunotherapy and re-
moval of the immunologic trigger, such as tera-
toma or another tumor, when applicable. Early 
tumor treatment is particularly important in 
achieving a good outcome.25,29 In most autoim-
mune encephalitides, antibody production and 
inflammatory changes occur behind the blood–
brain barrier, which probably explains the lim-
ited effectiveness of plasma exchange and of 
intravenous immune globulin, in contrast to the 
beneficial effects of these interventions in sys-
temic antibody-mediated diseases such as my-
asthenia gravis. Nevertheless, in practice, most 
patients are treated with glucocorticoids, intra-
venous immune globulin, or plasma exchange, 
and if there is no clinical response, rituximab 
and cyclophosphamide are used.25 Rituximab is 
usually effective in refractory cases, and it ap-
pears to reduce the risk of a clinical relapse,25 
which accounts for its increasing use as an 
initial treatment.44 Although hyperthermia, 
muscle rigidity, mutism, and coma may develop 
in patients with anti-NMDAR encephalitis in-
dependent of the use of neuroleptic agents, 
studies suggest an increased susceptibility to 
the adverse effects of these drugs (e.g., the 
neuroleptic malignant syndrome); the mecha-
nisms underlying this complication are un-
known.45
The speed of recovery, degree of residual 
deficit, and frequency of relapse vary according 
to the type of autoimmune encephalitis. In a 
series of 577 patients with anti-NMDAR en-
cephalitis, 53% had clinical improvement within 
4 weeks, and 81% had substantial recovery (i.e., 
mild or no residual symptoms) at 24 months.25 
Another study showed that patients with anti-
LGI1 encephalitis had a more rapid response but 
that only 70% had substantial recovery at 24 
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months.21 For autoimmune encephalitides that 
are frequently associated with cancer, such as 
anti-AMPAR and anti-GABABR encephalitides, 
the rate of response to immunotherapy is lower, 
particularly when additional paraneoplastic 
mechanisms such as antibodies and cytotoxic 
T-cell responses against intracellular antigens 
are identified.29
For all types of autoimmune encephalitides, 
prompt immunotherapy has been associated 
with a favorable outcome; spontaneous clinical 
improvement is infrequent.25 The frequency of 
clinical relapse in the encephalitides associated 
with antibodies against NMDAR, AMPAR, LGI1, 
CASPR2, or DPPX ranges from 12 to 35%.8,21,24,25,29 
Relapses often occur when immunotherapy is 
reduced or discontinued.23 There is anecdotal 
evidence that cases of anti-LGI1 or anti-NMDAR 
encephalitis can relapse many years after the 
first episode. Relapses may herald recurrence of 
the associated tumor or a tumor that was missed 
in the initial episode.25 Immunotherapy and 
treatment of the tumor, if it was missed initially, 
usually result in improvement.
Fu t ur e S t udies
The discovery of the category of autoimmune 
encephalitides has changed the diagnostic and 
treatment approach to many neurologic or psy-
chiatric syndromes that were previously consid-
ered to be idiopathic. The rapid increase in the 
number of syndromes and autoantibodies iden-
tified over the past 10 years suggests that other 
autoimmune encephalitides have yet to be dis-
covered.1 Antibody titers correlate imperfectly 
with the course of the disease and may remain 
detectable (albeit at a low titer) after clinical re-
covery,27 indicating the need to identify biomark-
ers for prognosis and treatment decisions. The 
usefulness of neuropsychological testing, elec-
troencephalography,46 advanced neuroimaging,47 
and 18F-f luorodeoxyglucose–positron-emission 
tomography48 in the diagnosis of autoimmune 
encephalitides, assessment of treatment effi-
cacy, and prognosis requires investigation. Pre-
liminary data suggest that the protracted clini-
cal course of anti-NMDAR encephalitis is due 
to antibody production by long-lived plasma 
cells in the brain,35 along with the antibody ef-
fects on brain circuitry.41 Further studies are 
needed to confirm these hypotheses and deter-
mine whether they apply to other autoimmune 
encephalitides. Studies of how autoantibodies 
alter the structure and function of synaptic 
proteins and cause symptoms are critical for an 
understanding of the underlying pathogenic 
mechanisms, which in turn could lead to the 
development of new treatment strategies. For 
example, the observation that NMDAR anti-
bodies alter the interaction between NMDAR 
and the ephrin-B2 receptor49 and that a soluble 
agonist of the ephrin-B2 receptor antagonizes 
the antibody effects suggests a potential treat-
ment strategy.41 Finally, knowing how antibod-
ies cause symptoms, such as the psychosis 
caused by anti-NMDAR antibodies, may help to 
understand psychiatric diseases in which the 
same receptors may be altered by other mecha-
nisms.50
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the full text of this article at NEJM.org.
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